ZNF833P: A Potential Drug Target and Biomarker for Various Diseases

Target Name: ZNF833P

NCBI ID: G401898

ZNF833P

Other Name(s): ZNF833 | Zinc finger protein 833, pseudogene | zinc finger protein 833, pseudogene

ZNF833P: A Potential Drug Target and Biomarker for Various Diseases

ZNF833P, also known as ZNF833, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Zinc finger gene family (ZNF), which is known for its role in regulating gene expression and cell development. ZNF833P is a potential drug target and has been identified as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ZNF gene family consists of more than 200 genes that encode for proteins with similar domains to the zinc finger protein. These proteins are characterized by a conserved catalytic core and a variable N-terminus that includes a zinc ion-binding site and a transmembrane region. ZNF833P is a member of the ZNF8 gene family and is characterized by a single open reading frame (ORF) of 24 amino acids.

ZNF833P is expressed in a variety of tissues and organs, including the brain, heart, and kidneys. It is highly expressed in the brain, where it is expressed in the neurotransmitter-producing neurons and glial cells. ZNF833P is also expressed in other tissues, including the heart and kidneys, where it is involved in regulating various physiological processes, such as cell proliferation, migration, and survival.

One of the unique features of ZNF833P is its potential as a drug target. The zinc finger protein has been shown to play a role in various cellular processes, including cell signaling, gene regulation, and disease. ZNF833P is known to be involved in several signaling pathways, including the Wnt/FGF signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway.

In addition to its potential as a drug target, ZNF833P has also been identified as a biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF833P has been shown to be involved in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. It has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target and biomarker, ZNF833P is also of interest as a potential therapeutic agent. ZNF833P can be expressed and purified from various cell lines and tissues, and studies have shown that it can be used to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that ZNF833P can be used to treat various types of cancer, including breast, ovarian, and colorectal cancers, by inhibiting its activity in cell signaling pathways.

In conclusion, ZNF833P is a protein that is of interest as a potential drug target and biomarker for various diseases. Its unique characterization as a member of the ZNF gene family and its potential involvement in various signaling pathways make it a promising target for further research and development. Further studies are needed to fully understand the role of ZNF833P in disease and to explore its potential as a therapeutic agent.

Protein Name: Zinc Finger Protein 833, Pseudogene

The "ZNF833P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF833P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets